People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.2B | 2021 |
| Lycia Therapeutics, Inc. | Director | Biotechnology | Series C | $75.0M | $314.3M | 2026 |
| Kallyope, Inc. | — | Biotechnology | Series B | $28.1M | $1.1B | 2015 |
| Anacor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $19.4M | $83.6M | 2013 |
William Rieflin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Rieflin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 2 | 8 |
| Laurent Fischer | 2 | 4 |
| Ming Fang | 2 | 4 |
| TIM ANDERSON | 2 | 3 |
| Aetna Wun Trombley | 2 | 3 |
| Michael O'Donnell | 1 | 11 |
| David Perry | 1 | 11 |
| Adam Goulburn | 1 | 10 |
| Mark Leschly | 1 | 9 |
| Terry McGuire | 1 | 8 |
| Tim Kutzkey | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Paul Klingenstein | 1 | 6 |
| Anders Hove | 1 | 4 |
| Joshua Wolfe | 1 | 4 |
| Geoffrey Parker | 1 | 3 |
| Richard Markham | 1 | 3 |
| Paul Berns | 1 | 3 |
| Kenneth Clark | 1 | 3 |
| Nancy Thornberry | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.